Condition: Unresectable/Metastatic Melanoma · Sponsor: Canadian Cancer Trials Group
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
This description comes directly from the study's public registry record.
Janet Dancey · 613-533-6430 · jdancey@ctg.queensu.ca
Always discuss trial participation with your own doctor first.
| Mildura Base Public Hospital | Victoria, Mildura, Australia | Recruiting |
| Coffs Habour Health Campus - NCCI | Coffs Harbour, New South Wales, Australia | Recruiting |
| Calvary Mater Newcastle Hospital | Waratah, New South Wales, Australia | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Sunshine Coast University Hospital | Birtinya, Queensland, Australia | Recruiting |
| Cairns Hospital | Cairns, Queensland, Australia | Recruiting |
| Gold Coast University Hospital | Southport, Queensland, Australia | Recruiting |
| The Queen Elizabeth Hospital | Woodville, South A., Australia | Recruiting |
| Monash Medical Centre | Clayton, Victoria, Australia | Recruiting |
| Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Royal Brisbane and Womens Hospital | Herston, Australia | Recruiting |
| Cross Cancer Institute | Edmonton, Alberta, Canada | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02821013